Return to Today's science sparks archives

2014-04-01

Fig 3. Multiple patterns of AR gain and amplification found in a single TMA core.

Fig 3. Multiple patterns of AR gain and amplification found in a single TMA core.
  • Merson S, Yang ZH, Brewer D, Olmos D, Eichholz A, McCarthy F, Fisher G, Kovacs G, Berney DM, Foster CS, Møller H, Scardino P, Cuzick J, Cooper CS, Clark JP on behalf of the Transatlantic Prostate Group

  • Br J Cancer. 2014 Mar 18;110(6):1655-62

2014-04-02

Fig 6. Quantification of lipid raft fluorescence assessed by average CTCF/area of TnT-forming and non-TnT-forming cells.

Fig 6. Quantification of lipid raft fluorescence assessed by average CTCF/area of TnT-forming and non-TnT-forming cells.
  • Thayanithy V, Babatunde V, Dickson EL, Wong P, Oh S, Ke X, Barlas A, Fujisawa S, Romin Y, Moreira AL, Downey RJ, Steer CJ, Subramanian S, Manova-Todorova K, Moore MA, Lou E

  • Exp Cell Res. 2014 Apr 15;323(1):178-88.

2014-04-03

Fig 1. Potential applications of ctDNA.

Fig 1. Potential applications of ctDNA.
  • Bettegowda C1, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr.

  • Sci Transl Med. 2014 Feb 19;6(224):224ra24

2014-04-04

Fig 8. Log-plot of concentrations that yield a 5% CEST effect for different chemical moieties.

Fig 8. Log-plot of concentrations that yield a 5% CEST effect for different chemical moieties.
  • Bokacheva L, Ackerstaff E, Lekaye HC, Zakian K, Koutcher JA

  • Phys Med Biol. 2014 Jan 20;59(2):R65-R127.

2014-04-07

Overall survival (randomised population; censored at crossover) for patients randomly assigned to vemurafenib or to dacarbazine (cutoff Feb 1, 2012)

Overall survival (randomised population; censored at crossover) for patients randomly assigned to vemurafenib or to dacarbazine (cutoff Feb 1, 2012)
  • McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid , Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A

  • Lancet Oncol. 2014 Mar;15(3):323-32.

2014-04-08

Fig 7. Combination of PU-H71 and bortezomib exhibits greater inhibition of tumor growth in A673 xenograft model in NSG mice.

Fig 7. Combination of PU-H71 and bortezomib exhibits greater inhibition of tumor growth in A673 xenograft model in NSG mice.
  • Ambati SR, Lopes EC, Kosugi K, Mony U, Zehir A, Shah SK, Taldone T, Moreira AL, Meyers PA, Chiosis G, Moore MA

  • Mol Oncol. 2014 Mar;8(2):323-36.

2014-04-09

Fig 1. Kaplan-Meier estimate of OS and EFS (N = 51) patients.

Fig 1. Kaplan-Meier estimate of OS and EFS (N = 51) patients.
  • Sauter CS, Barker JN, Lechner L, Zheng J, Devlin SM, Papadopoulos EB, Perales MA, Jakubowski AA, Goldberg JD, Koehne G, Ceberio I, Giralt S, Zelenetz AD, Moskowitz CH, Castro-Malaspina H

  • Biol Blood Marrow Transplant. 2014 Mar;20(3):354-60.

2014-04-10

Fig. 1 - Rationale for development and application of molecular imaging techniques to musculoskeletal radiology. Molecular imaging techniques promise molecular detection of underlying causes of skeletal abnormality or repair process at early time point, thus increasing diagnostic value.

Fig. 1 - Rationale for development and application of molecular imaging techniques to musculoskeletal radiology. Molecular imaging techniques promise molecular detection of underlying causes of skeletal abnormality or repair process at early time point, thus increasing diagnostic value.
  • Wilmot A, Gieschler S, Behera D, Gade TP, Reumann MK, Biswal S, Mayer-Kuckuk P

  • AJR Am J Roentgenol. 2013 Aug;201(2):264-77.

2014-04-11

Fig 4. Kaplan-Meier curves of overall survival.

Fig 4. Kaplan-Meier curves of overall survival.
  • Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grünwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B

  • Lancet Oncol. 2014 Mar;15(3):286-96.

2014-04-14

MSLN expression and clinicopathologic characteristics.

MSLN expression and clinicopathologic characteristics.
  • Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS

  • Clin Cancer Res. 2014 Feb 15;20(4):1020-8.

2014-04-15

L1CAM Expression in Human Brain Metastases.

L1CAM Expression in Human Brain Metastases.
  • Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E, Massagué J

  • Cell. 2014 Feb 27;156(5):1002-16.

2014-04-16

Validation of miR-9 repression by ΔEGFR.

Validation of miR-9 repression by ΔEGFR.
  • Gomez GG1, Volinia S, Croce CM, Zanca C, Li M, Emnett R, Gutmann DH, Brennan CW, Furnari FB, Cavenee WK

  • Cancer Res. 2014 Mar 1;74(5):1429-39.

2014-04-17

mir-451-type substrates generate functional regulatory RNAs in Drosophila.

mir-451-type substrates generate functional regulatory RNAs in Drosophila.
  • Yang JS1, Smibert P, Westholm JO, Jee D, Maurin T, Lai EC

  • Nucleic Acids Res. 2014 Feb;42(3):1987-2002.

2014-04-18

Fig 1. The formation of an unexpected heterocyclic scaffold, a benzoxazole, in a three-component reaction between a ketone, isocyanide, and 2-aminophenol was encountered.

Fig 1. The formation of an unexpected heterocyclic scaffold, a benzoxazole, in a three-component reaction between a ketone, isocyanide, and 2-aminophenol was encountered.
  • Váradi A, Palmer TC, Notis PR, Redel-Traub GN, Afonin D, Subrath JJ, Pasternak GW, Hu C, Sharma I, Majumdar S

  • Org Lett. 2014 Mar 21;16(6):1668-71.

2014-04-21

Cumulative incidence of relapse.

Cumulative incidence of relapse.
  • Marks DI1, Woo KA, Zhong X, Appelbaum FR, Bachanova V, Barker JN, Brunstein CG, Gibson J, Kebriaei P, Lazarus HM, Olsson R, Perales MA, Pidala J, Savani B, Rocha V, Eapen M

  • Haematologica. 2014 Feb;99(2):322-8.
Open Access button

2014-04-22

Fig 1. Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) levels in liver (A) and adipose tissue (B) of RBP−/− or wild type mice.

Fig 1. Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) levels in liver (A) and adipose tissue (B) of RBP−/− or wild type mice.
  • Carta G, Murru E, Cordeddu L, Ortiz B, Giordano E, Belury MA, Quadro L, Banni S

  • Nutrients. 2014 Mar 24;6(3):1262-72.

2014-04-23

Fig 1. Kaplan-Meier estimate of OS and EFS (N = 51) patients.

Fig 1. Kaplan-Meier estimate of OS and EFS (N = 51) patients.
  • Sauter CS, Barker JN, Lechner L, Zheng J, Devlin SM, Papadopoulos EB, Perales MA, Jakubowski AA, Goldberg JD, Koehne G, Ceberio I, Giralt S, Zelenetz AD, Moskowitz CH, Castro-Malaspina H

  • Biol Blood Marrow Transplant. 2014 Mar;20(3):354-60.

2014-04-24

Fig 1. Screening of the small-molecule library.

Fig 1. Screening of the small-molecule library.
  • Santiesteban OJ, Kaittanis C, Perez JM

  • Small. 2014 Mar;10(6):1202-11.

2014-04-25

Fig 1. Generation and analysis of Eomes-GFP knockin reporter mice.

Fig 1. Generation and analysis of Eomes-GFP knockin reporter mice.
  • Daussy C, Faure F, Mayol K, Viel S, Gasteiger G, Charrier E, Bienvenu J, Henry T, Debien E, Hasan UA, Marvel J, Yoh K, Takahashi S, Prinz I, de Bernard S, Buffat L, Walzer T

  • J Exp Med. 2014 Mar 10;211(3):563-77.

2014-04-28

Fig 1. Therapeutic activity of combined inhibition of EGFR, HER3, and the PI3K-Akt pathway in TNBC preclinical models.

Fig 1. Therapeutic activity of combined inhibition of EGFR, HER3, and the PI3K-Akt pathway in TNBC preclinical models.
  • Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M

  • Sci Signal. 2014 Mar 25;7(318):ra29.

2014-04-29

Fig 2. Whole-body scan showing multiple metastatic disease sites in bone.

Fig 2. Whole-body scan showing multiple metastatic disease sites in bone.
  • Dauer LT, Williamson MJ, Humm J, O'Donoghue J, Ghani R, Awadallah R, Carrasquillo J, Pandit-Taskar N, Aksnes AK, Biggin C, Reinton V, Morris M, St Germain J

  • Health Phys. 2014 Apr;106(4):494-504.

2014-04-30

Fig 1. Cumulative risk of prostate cancer diagnosis.

Fig 1. Cumulative risk of prostate cancer diagnosis.
  • Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A

  • BMJ. 2014 Mar 28;348:g2296.
Open Access button

2014-05-01

Fig 1. Transplantation physician demographics.

Fig 1. Transplantation physician demographics.
  • Burns LJ, Gajewski JL, Majhail NS, Navarro W, Perales MA, Shereck E, Selby GB, Snyder EL, Woolfrey AE, Litzow MR

  • Biol Blood Marrow Transplant. 2014 May;20(5):617-21

2014-05-02

Fig 2. F98 glioma in rat cerebellar organotypic cultures with and without riluzole following radiation treatment.

Fig 2. F98 glioma in rat cerebellar organotypic cultures with and without riluzole following radiation treatment.
  • Yohay K, Tyler B, Weaver KD, Pardo AC, Gincel D, Blakeley J, Brem H, Rothstein JD

  • J Neurosurg. 2014 Apr;120(4):854-63.

2014-05-05

Fig 1. Commensal bacteria-mediated mechanisms of protection against intestinal pathogens. (1) Commensal bacterial communities consume nutrients and energy sources, depriving pathogens of a niche. (2) Microbiota-derived metabolic by-products directly inhibit pathogens. (3) Commensal bacteria stimulate host immune cells and drive basal expression of host defense factors.

Fig 1. Commensal bacteria-mediated mechanisms of protection against intestinal pathogens. (1) Commensal bacterial communities consume nutrients and energy sources, depriving pathogens of a niche. (2) Microbiota-derived metabolic by-products directly inhibit pathogens. (3) Commensal bacteria stimulate host immune cells and drive basal expression of host defense factors.
  • Abt MC, Pamer EG

  • Curr Opin Immunol. 2014 Apr 8;29C:16-22.

2014-05-06

Fig 3. Csnk1a1 suppression activates a p53 response. (A) In leukemia cells with shRNA-mediated suppression of Csnk1a1, p53 signatures are enriched by GSEA

Fig 3. Csnk1a1 suppression activates a p53 response. (A) In leukemia cells with shRNA-mediated suppression of Csnk1a1, p53 signatures are enriched by GSEA
  • Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL

  • J Exp Med. 2014 Apr 7;211(4):605-12.

2014-05-07

Fig 1. Cumulative incidence of sustained donor engraftment according to the presence of HLA-Abs after myeloablative conditioning (n = 67). The presence of pre-existing HLA-Abs (nonspecific or donor-specific) did not influence the cumulative incidence of sustained donor neutrophil engraftment.

Fig 1. Cumulative incidence of sustained donor engraftment according to the presence of HLA-Abs after myeloablative conditioning (n = 67). The presence of pre-existing HLA-Abs (nonspecific or donor-specific) did not influence the cumulative incidence of sustained donor neutrophil engraftment.
  • Dahi PB, Barone J, Devlin SM, Byam C, Lubin M, Ponce DM, Giralt S, Kernan NA, Scaradavou A, Hsu SH, Barker JN

  • Biol Blood Marrow Transplant. 2014 May;20(5):735-9.

2014-05-08

Fig 3. Market concentration of autologous breast reconstruction (1998 to 2010).

Fig 3. Market concentration of autologous breast reconstruction (1998 to 2010).
  • Albornoz CR, Cordeiro PG, Mehrara BJ, Pusic AL, McCarthy CM, Disa JJ, Matros E

  • Plast Reconstr Surg. 2014 Mar;133(3):463-70.

2014-05-09

Fig 1.Stage distribution in bladder cancer patients. (A) Overall American Joint Committee on Cancer (AJCC) clinical stage, (B) overall AJCC pathologic stage, (C) clinical tumor (T) stage, (D) pathologic tumor (T) stage.

Fig 1.Stage distribution in bladder cancer patients. (A) Overall American Joint Committee on Cancer (AJCC) clinical stage, (B) overall AJCC pathologic stage, (C) clinical tumor (T) stage, (D) pathologic tumor (T) stage.
  • Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, Rosenberg JE, Kamat AM, Virgo KS, Blute ML, Zietman AL, Efstathiou JA

  • Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1048-56.

2014-05-12

a MIP FDG PET image of patient 39 with a small lung tumor in the right upper lobe with a low FDG activity (SUVmax 1.5) and TLG2.5 < 50 ml*SUV. b Axial slice of the tumor in the right upper lobe.

a MIP FDG PET image of patient 39 with a small lung tumor in the right upper lobe with a low FDG activity (SUVmax 1.5) and TLG2.5 < 50 ml*SUV. b Axial slice of the tumor in the right upper lobe.
  • Burger IA, Vargas HA, Apte A, Beattie BJ, Humm JL, Gonen M, Larson SM, Ross Schmidtlein C

  • Nucl Med Biol. 2014 May-Jun;41(5):410-8.

2014-05-13

Fig 2. Overall survival, patients treated with single-fraction radiosurgery (green line) versus hypofractionated radiosurgery (hypo) (blue line) (P=.073). A color version of this figure is available at www.redjournal.org.

Fig 2. Overall survival, patients treated with single-fraction radiosurgery (green line) versus hypofractionated radiosurgery (hypo) (blue line) (P=.073). A color version of this figure is available at www.redjournal.org.
  • Folkert MR, Bilsky MH, Tom AK, Oh JH, Alektiar KM, Laufer I, Tap WD, Yamada Y

  • Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1085-91.

2014-05-14

Fig 1. Percent depth dose (PDD) curve for an intraoperative 32P brachytherapy plaque, with measurements for radiation dose at a depth relative to prescription dose (10 Gy to 1-mm depth).

Fig 1. Percent depth dose (PDD) curve for an intraoperative 32P brachytherapy plaque, with measurements for radiation dose at a depth relative to prescription dose (10 Gy to 1-mm depth).
  • Tong WY, Folkert MR, Greenfield JP, Yamada Y, Wolden SL

  • J Neurosurg Pediatr. 2014 Apr;13(4):388-92

2014-05-15

Enrolling site location, with size of circle corresponding to participation volume (small circle, 1 patient; medium circles, 10 patients; large circles, 100 patients) comprising 51 sites in 39 cities.

Enrolling site location, with size of circle corresponding to participation volume (small circle, 1 patient; medium circles, 10 patients; large circles, 100 patients) comprising 51 sites in 39 cities.
  • Grogan EL, Deppen SA, Ballman KV, Andrade GM, Verdial FC, Aldrich MC, Chen CL, Decker PA, Harpole DH, Cerfolio RJ, Keenan RJ, Jones DR, D'Amico TA, Shrager JB, Meyers BF, Putnam JB Jr

  • Ann Thorac Surg. 2014 Apr;97(4):1142-8.

2014-05-16

EWSR1-NR4A3–positive EMC (EMC 2)

EWSR1-NR4A3–positive EMC (EMC 2)
  • Agaram NP, Zhang L, Sung YS, Singer S, Antonescu CR

  • Hum Pathol. 2014 May;45(5):1084-91.

2014-05-19

A Single Enhancer Rearrangement Deregulates Two Oncogenic Drivers.

A Single Enhancer Rearrangement Deregulates Two Oncogenic Drivers.
  • Koche RP, Armstrong SA.

  • Cancer Cell. 2014 Apr 14;25(4):407-8.

2014-05-20

Fig 1. Female POP procedures performed by ABU certifying and recertifying urologists from 2003 to 2012 by procedure type.

Fig 1. Female POP procedures performed by ABU certifying and recertifying urologists from 2003 to 2012 by procedure type.
  • Elterman DS, Chughtai BI, Vertosick E, Maschino A, Eastham JA, Sandhu JS

  • J Urol. 2014 Apr;191(4):1022-7.

2014-05-21

Fig 1. Decay scheme for 223Ra.

Fig 1. Decay scheme for 223Ra.
  • Pandit-Taskar N, Larson SM, Carrasquillo JA

  • J Nucl Med. 2014 Feb;55(2):268-74.

2014-05-22

Graphical Abstract

Graphical Abstract
  • Chakravarty AK, Smith P, Jalan R, Shuman S

  • Cell Rep. 2014 Apr 24;7(2):339-47.
Open Access button

2014-05-23

Fig 1. Summary of the histologic, immunohistochemical, and genetic characteristics of cases included in this study.

Fig 1. Summary of the histologic, immunohistochemical, and genetic characteristics of cases included in this study.
  • Sakr RA, Weigelt B, Chandarlapaty S, Andrade VP, Guerini-Rocco E, Giri D, Ng CK, Cowell CF, Rosen N, Reis-Filho JS, King TA

  • Clin Cancer Res. 2014 May 1;20(9):2326-37.

2014-05-27

Fig 3c.  The distribution of paxillin was visualized by immunofluorescence in HBEC3-p53KD-K-Rasv12 Control and BRMS1 KD cells.

Fig 3c. The distribution of paxillin was visualized by immunofluorescence in HBEC3-p53KD-K-Rasv12 Control and BRMS1 KD cells.
  • Hall EH, Liu Y, Xiao A, Shock L, Brautigan DL, Mayo MW, Adusumilli PS, Jones DR.

  • PLoS One. 2014 Apr 24;9(4):e95869.
Open Access button

2014-05-28

Fig 3. Plot showing the growth rate over time for the 234 patients who had any evidence of tumor growth.

Fig 3. Plot showing the growth rate over time for the 234 patients who had any evidence of tumor growth.
  • Burotto M, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T

  • PLoS One. 2014 May 5;9(5):e96316.
Open Access button

2014-05-29

Fig 2. Treg cell ablation has no apparent impact on thymic function in neonates. Neonates were injected i.p with DT or PBS on day 3 after birth, and cell suspensions from the thymus were prepared on day 7 after birth. A. FACS analysis of CD4+ and CD8+ single positive (SP), double positive (DP) and double negative (DN) thymocytes.

Fig 2. Treg cell ablation has no apparent impact on thymic function in neonates. Neonates were injected i.p with DT or PBS on day 3 after birth, and cell suspensions from the thymus were prepared on day 7 after birth. A. FACS analysis of CD4+ and CD8+ single positive (SP), double positive (DP) and double negative (DN) thymocytes.
  • Moltedo B, Hemmers S, Rudensky AY

  • PLoS One. 2014 Jan 23;9(1):e86762.
Open Access button

2014-05-30

Fig 1. Propagation of neutral poly-G mutations in normal and neoplastic somatic cell lineages—schematic representation.

Fig 1. Propagation of neutral poly-G mutations in normal and neoplastic somatic cell lineages—schematic representation.
  • Naxerova K, Brachtel E, Salk JJ, Seese AM, Power K, Abbasi B, Snuderl M, Chiang S, Kasif S, Jain RK

  • Proc Natl Acad Sci U S A. 2014 May 6;111(18):E1889-98

2014-06-02

Fig 3. Characterization of MNP AML. (A) Histological analysis of blood (a), liver (b), spleen (c), and BM (d) of an MNP recipient mouse. Scale bar: 12 μm for (a–c) and 30 μm for (d).

Fig 3. Characterization of MNP AML. (A) Histological analysis of blood (a), liver (b), spleen (c), and BM (d) of an MNP recipient mouse. Scale bar: 12 μm for (a–c) and 30 μm for (d).
  • Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW

  • Cancer Cell. 2014 May 12;25(5):652-65.

2014-06-03

Fig 2. Variability in the Signaling Profile Allows Partioning of CLL Patients Into Distinct Prognostic Groups. A Graphic representation of all five phosphoresponses for CLL patients (blue, n = 110) as compared to the healthy controls (red, n = 11).

Fig 2. Variability in the Signaling Profile Allows Partioning of CLL Patients Into Distinct Prognostic Groups. A Graphic representation of all five phosphoresponses for CLL patients (blue, n = 110) as compared to the healthy controls (red, n = 11).
  • Palomba ML, Piersanti K, Ziegler CG, Decker H, Cotari JW, Bantilan K, Rijo I, Gardner JR, Heaney M, Bemis D, Balderas R, Malek SN, Seymour E, Zelenetz AD, van den Brink MR, Altan-Bonnet G

  • PLoS One. 2014 Jan 29;9(1):e79987.
Open Access button

2014-06-04

Fig 2. The V3 linker dictates the kinetics of PKCε and PKCθ recruitment. 5C.C7 T cells expressing the indicated GFP-labeled nPKC chimeras together with PKCθ-RFP were imaged by TIRF microscopy and UV irradiated on surfaces containing photoactivatable pMHC. (A) Representative time-lapse montages (time shown in seconds at lower right corner), with the time and region of UV irradiation indicated by white circles.

Fig 2. The V3 linker dictates the kinetics of PKCε and PKCθ recruitment. 5C.C7 T cells expressing the indicated GFP-labeled nPKC chimeras together with PKCθ-RFP were imaged by TIRF microscopy and UV irradiated on surfaces containing photoactivatable pMHC. (A) Representative time-lapse montages (time shown in seconds at lower right corner), with the time and region of UV irradiation indicated by white circles.
  • Basu R, Chen Y, Quann EJ, Huse M

  • PLoS One. 2014 Apr 21;9(4):e95531.
Open Access button

2014-06-05

In Vivo CRISPR/Cas9 Confirmed that Mll3 Is a Haploinsufficient Tumor Suppressor in AML.

In Vivo CRISPR/Cas9 Confirmed that Mll3 Is a Haploinsufficient Tumor Suppressor in AML.
  • Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW

  • Cancer Cell. 2014 May 12;25(5):652-65.

2014-06-06

Fig 18. Axial postcontrast three-dimensional T1-weighted image shows susceptibility artifact from a biopsy clip in the left breast (white circle).

Fig 18. Axial postcontrast three-dimensional T1-weighted image shows susceptibility artifact from a biopsy clip in the left breast (white circle).
  • Palestrant S, Comstock CE, Moy L

  • Radiol Clin North Am. 2014 May;52(3):563-583.

2014-06-09

Schematic illustrating important properties of MSMs and their construction.

Schematic illustrating important properties of MSMs and their construction.
  • Chodera JD, Noé F

  • Curr Opin Struct Biol. 2014 Apr;25C:135-144.

2014-06-10

Biological responses induced by low doses of radiation.

Biological responses induced by low doses of radiation.
  • Brooks AL, Dauer LT

  • Semin Nucl Med. 2014 May;44(3):179-186

2014-06-11

Fig 1. Overview of molecular JAK signaling.

Fig 1. Overview of molecular JAK signaling.
  • Meyer SC, Levine RL

  • Clin Cancer Res. 2014 Apr 15;20(8):2051-9.

2014-06-12

Comparison of nuclear medicine (NM) and radiation oncology (RO) volumes in a case example of a patient with non-Hodgkin lymphoma with paraspinal disease.

Comparison of nuclear medicine (NM) and radiation oncology (RO) volumes in a case example of a patient with non-Hodgkin lymphoma with paraspinal disease.
  • Terezakis SA, Schöder H, Kowalski A, McCann P, Lim R, Turlakov A, Gonen M, Barker C, Goenka A, Lovie S, Yahalom J

  • Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):376-83.

2014-06-13

Fig 1. DMF controls rotation of magnetic nanoparticles.

Fig 1. DMF controls rotation of magnetic nanoparticles.
  • Zhang E, Kircher MF, Koch M, Eliasson L, Goldberg SN, Renström E

  • ACS Nano. 2014 Apr 22;8(4):3192-201.

2014-06-16

Fig 1. NF1-null melanoma cell lines express high levels of activated RAS.

Fig 1. NF1-null melanoma cell lines express high levels of activated RAS.
  • Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB

  • Cancer Res. 2014 Apr 15;74(8):2340-50.

2014-06-17

Fig 1. Schematic workflows of the Oqtans use cases.

Fig 1. Schematic workflows of the Oqtans use cases.
  • Sreedharan VT, Schultheiss SJ, Jean G, Kahles A, Bohnert R, Drewe P, Mudrakarta P, Görnitz N, Zeller G, Rätsch G

  • Bioinformatics. 2014 May 1;30(9):1300-1.

2014-06-18

Fig 3. MEK Is Less Susceptible to Inhibition when Activated by CRAF Than by BRAF V600E.

Fig 3. MEK Is Less Susceptible to Inhibition when Activated by CRAF Than by BRAF V600E.
  • Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N

  • Cancer Cell. 2014 May 12;25(5):697-710.

2014-06-19

Detection of proBDNF-HA and p75NTR and Secretion of proBDNF from Hippocampal Neurons of probdnf-HA/+ Mice.

Detection of proBDNF-HA and p75NTR and Secretion of proBDNF from Hippocampal Neurons of probdnf-HA/+ Mice.
  • Yang J, Harte-Hargrove LC, Siao CJ, Marinic T, Clarke R, Ma Q, Jing D, Lafrancois JJ, Bath KG, Mark W, Ballon D, Lee FS, Scharfman HE, Hempstead BL

  • Cell Rep. 2014 May 8;7(3):796-806.

2014-06-20

Fig 1. The expression of NET protein in neuroblastoma cell lines.

Fig 1. The expression of NET protein in neuroblastoma cell lines.
  • Zhang H, Huang R, Cheung NK, Guo H, Zanzonico PB, Thaler HT, Lewis JS, Blasberg RG

  • Clin Cancer Res. 2014 Apr 15;20(8):2182-91.

2014-06-23

A 62-year-old man with gastric cancer, who underwent FDG PET/CT for work-up of metastatic disease and screening colonoscopy, was found to have a 30 mm tubular adenoma in the descending colon.

A 62-year-old man with gastric cancer, who underwent FDG PET/CT for work-up of metastatic disease and screening colonoscopy, was found to have a 30 mm tubular adenoma in the descending colon.
  • Golluba M,Grewalb R,Panuc N, Thipphavongd S,Sohna M, Zhenge J, Moskowitze C

  • Clin Rad. 2014 June;69(6):611-18.

2014-06-24

Fig 1. Baseline and Follow-Up CT Scans. Baseline (Left) and Follow-Up (Right) Positron Emission Tomography/CT Scans of a 48-Year-Old Patient With Triple-Negative Breast Cancer With Right Lower Lobe Lung (Red Arrow) and T11 Metastases (Blue Arrow).

Fig 1. Baseline and Follow-Up CT Scans. Baseline (Left) and Follow-Up (Right) Positron Emission Tomography/CT Scans of a 48-Year-Old Patient With Triple-Negative Breast Cancer With Right Lower Lobe Lung (Red Arrow) and T11 Metastases (Blue Arrow).
  • Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, Moynahan ME, D'Andrea G, Lim K, Reddington L, Haque S, Patil S, Bauman L, Vukovic V, El-Hariry I, Hudis C, Modi S

  • Clin Breast Cancer. 2014 Jun;14(3):154-60.

2014-06-25

Fig 1. Biosynthesis of SAM and retrosynthesis of SAM, SeAM, and their chalcogen–alkyl analogues.

Fig 1. Biosynthesis of SAM and retrosynthesis of SAM, SeAM, and their chalcogen–alkyl analogues.
  • Bothwell IR, Luo M

  • Org Lett. 2014 Jun 6;16(11):3056-9.

2014-06-26

Fig 2. The Ub Y59-E51 loop. (B) Overlay of 1H-15N HSQC spectra for wild-type Ub (black contours) and Y59F Ub (magenta contours).

Fig 2. The Ub Y59-E51 loop. (B) Overlay of 1H-15N HSQC spectra for wild-type Ub (black contours) and Y59F Ub (magenta contours).
  • Chong RA, Wu K, Spratt DE, Yang Y, Lee C, Nayak J, Xu M, Elkholi R, Tappin I, Li J, Hurwitz J, Brown BD, Chipuk JE, Chen ZJ, Sanchez R, Shaw GS, Huang L, Pan ZQ

  • Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8434-9.

2014-06-27

Fig 2. Mass spectrum and UV trace of β-hCG(chitobiose)2(GalNAc)4[S1–Q145] glycoprotein.

Fig 2. Mass spectrum and UV trace of β-hCG(chitobiose)2(GalNAc)4[S1–Q145] glycoprotein.
  • Fernández-Tejada A, Vadola PA, Danishefsky SJ

  • J Am Chem Soc. 2014 Jun 11;136(23):8450-8

2014-06-30

Fig 3. Modeling the time course of the adverse event (AE) of fatigue with sunitinib treatment using the repeated-measures and random intercept-slope models.

Fig 3. Modeling the time course of the adverse event (AE) of fatigue with sunitinib treatment using the repeated-measures and random intercept-slope models.
  • Cella D, Davis MP, Négrier S, Figlin RA, Michaelson MD, Bushmakin AG, Cappelleri JC, Sandin R, Korytowsky B, Charbonneau C, Matczak E, Motzer RJ

  • Cancer. 2014 Jun 15;120(12):1871-80.

2014-07-01

Fig 2. Nucleosomal demethylation by LSD1 and Rcor proteins.

Fig 2. Nucleosomal demethylation by LSD1 and Rcor proteins.
  • Upadhyay G, Chowdhury AH, Vaidyanathan B, Kim D, Saleque S

  • Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8071-6.